NRAS mutations occur in 3.03% of all cancers (Consortium et al., 2017), predominantly in skin (10%–25%) (Jakob et al., 2012), acute myeloid leukemia (9.76%) (Consortium et al., 2017), and colon (∼4%) (Cicenas et al., 2017). Here, NRAS is linked to cancer.